- BetterLife Pharma Inc. reported **no revenue** for the three and six months ended July 31, 2025, incurring **net losses of $504,111 and $711,166**, respectively, which were lower than the prior comparable periods.  **[1464165_0001477932-25-007165_betrf_ex991.htm:5]** 
- The company's operating expenses significantly decreased to **$521,805** for the three months and **$832,488** for the six months ended July 31, 2025, primarily due to minimized discretionary consulting, professional, and research and development expenses.  **[1464165_0001477932-25-007165_betrf_ex991.htm:5]** 
- As of July 31, 2025, BetterLife Pharma Inc. had an **accumulated deficit of $119,301,932** and a **working capital deficiency of $5,757,486**, leading to **substantial doubt about its ability to continue as a going concern**.  **[1464165_0001477932-25-007165_betrf_ex992.htm:4]** **[1464165_0001477932-25-007165_betrf_ex991.htm:7]** **[1464165_0001477932-25-007165_betrf_ex991.htm:8]** 
- The company is actively developing several drug candidates, including **BETR-001** and **BETR-002** (both preclinical for mental health/anxiety), and **MM-001** (clinical stage for CIN) and **MM-003** (preclinical for viral infections), with regulatory statuses and development timelines under ongoing assessment.  **[1464165_0001477932-25-007165_betrf_ex991.htm:4]**

BetterLife Pharma (BETRF)